October 2019 FDA Recall Rifampin by Mylan Laboratories Limited (sterile Products Division) (D-0139-2020 - Failed Impurities/Degradation Specifications)

This Class II drug recall was voluntarily initiated by Mylan Laboratories Limited (sterile Products Division) on October 7, 2019 for the product Rifampin. The FDA reported the reason for recall as failed impurities/degradation specifications. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0139-2020

Reason for Recall
Failed Impurities/Degradation Specifications: discoloration due to elevated unknown impurity results which could decrease the effectiveness of the product.
Initiated
10-07-2019
Reported
10-16-2019
Quantity
19,165 vials

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Mylan Laboratories Limited (Sterile Products Division)
Nationwide in the USA
Rifampin for Injection, USP, 600 mg/vial, Rx only, Manufactured for: Mylan Institutional LLC, Rockford, IL 61103; NDC 67457-445-60.

Batch or Lot Expiration Information

Lot# Lot: 7008334, Exp April 2020; 7008417, Exp Oct 2020

Affected Packages Involved in this Recall